metabolic
NAD+ Injectable Pen
A pre-filled subcutaneous delivery system for pharmaceutical-grade NAD+, engineered for precise dosing without reconstitution. Each pen delivers 250mg of nicotinamide adenine dinucleotide through a fine-gauge needle system designed for patient self-administration.
For research and laboratory use only. Not for human consumption.
Quantity
Technical Data
Specifications
Technical Details
Quality Assurance
Certificate of Analysis
Certificate of Analysis
COA documentation is being prepared for this product.
Contact research@roehnrx.com for batch-specific testing data.
Research Overview
About NAD+ Injectable Pen
The NAD+ Injectable Pen represents the next evolution in coenzyme delivery — a ready-to-use, pre-filled pen device that eliminates the reconstitution step required by traditional lyophilized formulations. Each pen contains 250mg of pharmaceutical-grade nicotinamide adenine dinucleotide in a stabilized aqueous solution, delivered via a spring-loaded subcutaneous injection mechanism with a 31-gauge needle.
The pen format addresses a key limitation of conventional NAD+ administration: the complexity of reconstitution and the risk of dosing variability inherent in manual preparation. By providing a fixed-dose, factory-calibrated delivery system, the NAD+ Pen ensures consistent bioavailability across administrations while reducing preparation time from minutes to seconds.
Research into subcutaneous NAD+ delivery has demonstrated favorable pharmacokinetic profiles compared to oral precursor supplementation, with more direct tissue bioavailability. The pen's controlled delivery rate optimizes absorption kinetics, potentially reducing the discomfort sometimes associated with rapid subcutaneous NAD+ administration. Cold-chain logistics from manufacturing through delivery ensure compound stability throughout the supply chain.
